Gyre Therapeutics(GYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GYRE Gyre Therapeutics

交易中 11-26 15:37:55 EST

12.07

+0.44

+3.78%

最高12.42	最低11.65	成交量8.97万
今开11.65	昨收11.63	日振幅6.58%
总市值10.36亿	流通市值1.93亿	总股本8,582万
成交额107.74万	换手率0.56%	流通股本1,603万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"GYRE","market":"US","secType":"STK","nameCN":"Gyre Therapeutics","latestPrice":12.07,"timestamp":1732653305829,"preClose":11.63,"halted":0,"volume":89735,"delay":0,"floatShares":16031300,"shares":85822300,"eps":-1.218805,"marketStatus":"交易中","marketStatusCode":2,"change":0.44,"latestTime":"11-26 15:37:55 EST","open":11.65,"high":12.415,"low":11.65,"amount":1077375.10071,"amplitude":0.065778,"askPrice":12.25,"askSize":213,"bidPrice":12.08,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.218805,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1732654800000},"adr":0,"adjPreClose":11.63,"preHourTrading":{"tag":"盘前","latestPrice":12.21,"preClose":11.63,"latestTime":"09:28 EST","volume":3,"amount":36.63,"timestamp":1732631296039},"postHourTrading":{"tag":"盘后","latestPrice":11.63,"preClose":11.63,"latestTime":"16:01 EST","volume":650,"amount":7559.5,"timestamp":1732568515699},"volumeRatio":1.513717},"requestUrl":"/m/hq/s/GYRE","defaultTab":"news","newsList":[{"id":"1140323914","title":"异动解读 | Gyre Therapeutics盘中大涨5.2%,潜在治疗药物前景靓眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1140323914","media":"异动解读","labels":["movement"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140323914?lang=zh_cn&edition=full","pubTime":"2024-11-27 00:44","pubTimestamp":1732639461,"startTime":"0","endTime":"0","summary":"生物制药公司Gyre Therapeutics今日盘中大涨5.2%,引起市场广泛关注。\n\n分析人士指出,该公司的重磅产品Hydronidone正在进行相关临床试验,旨在治疗代谢功能障碍相关的脂肪性肝炎和肝纤维化。如果试验取得成功,这款新药或将成为公司的重要收入来源。\n\n另外,公司还在中国区域拥有多款管线产品,包括吡非尼酮、F573、F528和F230等,业务布局多元化,未来发展潜力可期。投资者对Gyre Therapeutics的长远前景持乐观态度,因此推动股价今日出现大涨行情。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Gyre Therapeutics盘中大涨5.2%,潜在治疗药物前景靓眼","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GYRE"],"gpt_icon":0},{"id":"2486885657","title":"Gyre Therapeutics, Inc.盘中异动 临近午盘急速上涨5.20%报12.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486885657","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486885657?lang=zh_cn&edition=full","pubTime":"2024-11-27 00:37","pubTimestamp":1732639027,"startTime":"0","endTime":"0","summary":"北京时间2024年11月27日00时37分，Gyre Therapeutics, Inc.股票出现波动，股价大幅拉升5.20%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.13%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127003707abe0f6a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127003707abe0f6a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2486203886","title":"Gyre Therapeutics, Inc.盘中异动 股价大涨5.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486203886","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486203886?lang=zh_cn&edition=full","pubTime":"2024-11-25 22:30","pubTimestamp":1732545039,"startTime":"0","endTime":"0","summary":"北京时间2024年11月25日22时30分，Gyre Therapeutics, Inc.股票出现波动，股价快速拉升5.93%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223039a2548b4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241125223039a2548b4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2485218659","title":"Gyre Therapeutics, Inc.盘中异动 下午盘快速下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485218659","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485218659?lang=zh_cn&edition=full","pubTime":"2024-11-23 03:06","pubTimestamp":1732302392,"startTime":"0","endTime":"0","summary":"北京时间2024年11月23日03时06分，Gyre Therapeutics, Inc.股票出现波动，股价急速下挫5.02%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.57%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123030632971a8294&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241123030632971a8294&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","GYRE"],"gpt_icon":0},{"id":"2485419542","title":"Gyre Therapeutics, Inc.2024财年第三财季实现净利润1.12百万美元，同比增加170.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2485419542","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485419542?lang=zh_cn&edition=full","pubTime":"2024-11-22 00:00","pubTimestamp":1732204826,"startTime":"0","endTime":"0","summary":"11月22日，Gyre Therapeutics, Inc.公布财报，公告显示公司2024财年第三财季净利润为1.12百万美元，同比增加170.89%；其中营业收入为25.49百万美元，每股基本收益为0.01美元。从资产负债表来看，Gyre Therapeutics, Inc.总负债26.77百万美元，其中短期债务694000.00美元，资产负债比为0.05，流动比率为3.73。机构评级：截至2024年11月22日，当前有1家机构对Gyre Therapeutics, Inc.目标价做出预测，其中目标均价为45.00美元，其中最低目标价为45.00美元，最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122000037abd50d98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122000037abd50d98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","GYRE"],"gpt_icon":0},{"id":"2483881492","title":"Gyre Therapeutics, Inc.盘中异动 股价大跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483881492","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483881492?lang=zh_cn&edition=full","pubTime":"2024-11-13 22:43","pubTimestamp":1731508998,"startTime":"0","endTime":"0","summary":"北京时间2024年11月13日22时43分，Gyre Therapeutics, Inc.股票出现波动，股价大幅下挫5.00%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.33%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111322431998e425fe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111322431998e425fe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","GYRE"],"gpt_icon":0},{"id":"2482085733","title":"Gyre Therapeutics, Inc.盘中异动 早盘股价大涨5.07%报17.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482085733","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482085733?lang=zh_cn&edition=full","pubTime":"2024-11-12 22:33","pubTimestamp":1731421994,"startTime":"0","endTime":"0","summary":"北京时间2024年11月12日22时33分，Gyre Therapeutics, Inc.股票出现异动，股价大幅拉升5.07%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222331498e42124&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111222331498e42124&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","BK4139","LENZ"],"gpt_icon":0},{"id":"2478648429","title":"Gyre Therapeutics, Inc.盘中异动 早盘大幅拉升5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2478648429","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478648429?lang=zh_cn&edition=full","pubTime":"2024-10-28 22:22","pubTimestamp":1730125339,"startTime":"0","endTime":"0","summary":"北京时间2024年10月28日22时22分，Gyre Therapeutics, Inc.股票出现异动，股价急速上涨5.21%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028222220971a2ad0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241028222220971a2ad0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","GYRE"],"gpt_icon":0},{"id":"2478939602","title":"Gyre Therapeutics, Inc.盘中异动 早盘股价大涨5.33%报14.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2478939602","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478939602?lang=zh_cn&edition=full","pubTime":"2024-10-25 22:07","pubTimestamp":1729865266,"startTime":"0","endTime":"0","summary":"北京时间2024年10月25日22时07分，Gyre Therapeutics, Inc.股票出现波动，股价大幅拉升5.33%。截至发稿，该股报14.83美元/股，成交量5826股，换手率0.01%，振幅2.63%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.74%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102522074698e3e845&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102522074698e3e845&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2477355532","title":"Gyre Therapeutics, Inc.盘中异动 早盘急速下跌5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2477355532","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477355532?lang=zh_cn&edition=full","pubTime":"2024-10-22 22:27","pubTimestamp":1729607264,"startTime":"0","endTime":"0","summary":"北京时间2024年10月22日22时27分，Gyre Therapeutics, Inc.股票出现异动，股价快速跳水5.16%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.88%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102222274498e3dca7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024102222274498e3dca7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","BK4139","LENZ"],"gpt_icon":0},{"id":"2474048831","title":"Gyre Therapeutics, Inc.盘中异动 下午盘股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2474048831","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2474048831?lang=zh_cn&edition=full","pubTime":"2024-10-12 01:35","pubTimestamp":1728668102,"startTime":"0","endTime":"0","summary":"北京时间2024年10月12日01时35分，Gyre Therapeutics, Inc.股票出现波动，股价快速拉升5.01%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.32%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410120135029719fbc3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410120135029719fbc3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","GYRE","BK4139"],"gpt_icon":0},{"id":"2472617023","title":"Gyre Therapeutics, Inc.盘中异动 早盘急速上涨5.00%报12.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2472617023","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2472617023?lang=zh_cn&edition=full","pubTime":"2024-10-03 23:18","pubTimestamp":1727968731,"startTime":"0","endTime":"0","summary":"北京时间2024年10月03日23时18分，Gyre Therapeutics, Inc.股票出现波动，股价急速拉升5.00%。截至发稿，该股报12.40美元/股，成交量1.9306万股，换手率0.02%，振幅3.30%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.99%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410032318519719e370&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202410032318519719e370&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GYRE","LENZ","BK4139"],"gpt_icon":0},{"id":"2469812603","title":"Gyre Therapeutics, Inc.盘中异动 急速下跌5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469812603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2469812603?lang=zh_cn&edition=full","pubTime":"2024-09-21 03:07","pubTimestamp":1726859258,"startTime":"0","endTime":"0","summary":"北京时间2024年09月21日03时07分，Gyre Therapeutics, Inc.股票出现异动，股价急速下挫5.02%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.68%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240921030738ab64ef80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240921030738ab64ef80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","GYRE","BK4139"],"gpt_icon":0},{"id":"2468257088","title":"Gyre Therapeutics, Inc.盘中异动 早盘股价大涨5.12%报14.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2468257088","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2468257088?lang=zh_cn&edition=full","pubTime":"2024-09-19 21:32","pubTimestamp":1726752733,"startTime":"0","endTime":"0","summary":"北京时间2024年09月19日21时32分，Gyre Therapeutics, Inc.股票出现波动，股价快速上涨5.12%。截至发稿，该股报14.58美元/股，成交量426股，换手率0.00%，振幅0.00%。Gyre Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.81%。Gyre Therapeutics, Inc.公司简介：Gyre Therapeutics Inc 是一家总部位于加利福尼亚州圣迭戈的生物制药公司，主要致力于 Hydronidone  的开发和商业化，该药物被用于治疗代谢功能障碍相关的脂肪性肝炎（MASH 相关肝纤维化（MASH 纤维化），以前在美国被称为非酒精性脂肪性肝炎（NASH）。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091921321398e3815e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024091921321398e3815e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GYRE","LENZ"],"gpt_icon":0},{"id":"2448557199","title":"Gyre Therapeutics宣布中国国家药品监督管理局已批准Avatrombopag Maleate片剂用于治疗CLD相关血小板减少症。","url":"https://stock-news.laohu8.com/highlight/detail?id=2448557199","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448557199?lang=zh_cn&edition=full","pubTime":"2024-07-03 04:05","pubTimestamp":1719950700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","BK4139","GYRE"],"gpt_icon":0},{"id":"2439670269","title":"Gyre Therapeutics Inc：获得中国国家药监局的临床批准将评估用于治疗肺动脉高压的F230","url":"https://stock-news.laohu8.com/highlight/detail?id=2439670269","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439670269?lang=zh_cn&edition=full","pubTime":"2024-05-31 04:25","pubTimestamp":1717100711,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","GYRE","LENZ"],"gpt_icon":0},{"id":"2439677464","title":"Gyre Therapeutics申请以1.5亿美元的价格进行混合货架发行——美国证券交易委员会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2439677464","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2439677464?lang=zh_cn&edition=full","pubTime":"2024-05-31 04:08","pubTimestamp":1717099683,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LENZ","GYRE","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.catalystbiosciences.com","stockEarnings":[{"period":"1week","weight":-0.0784},{"period":"1month","weight":-0.1816},{"period":"3month","weight":-0.0613},{"period":"6month","weight":0.1688},{"period":"1year","weight":-0.4008},{"period":"ytd","weight":-0.5473}],"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Gyre Therapeutics, Inc.在特拉华州注册成立。该公司及其子公司是一家生物制药公司，该公司是一家生物制药公司，致力于研究、开发、制造和商业化治疗器官纤维化的创新药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.09317},{"month":2,"riseRate":0.444444,"avgChangeRate":0.019313},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.058767},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.043227},{"month":5,"riseRate":0.444444,"avgChangeRate":0.126919},{"month":6,"riseRate":0.444444,"avgChangeRate":0.032517},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.009914},{"month":8,"riseRate":0.555556,"avgChangeRate":0.022526},{"month":9,"riseRate":0.2,"avgChangeRate":-0.158108},{"month":10,"riseRate":0.4,"avgChangeRate":-0.045163},{"month":11,"riseRate":0.6,"avgChangeRate":0.221962},{"month":12,"riseRate":0.555556,"avgChangeRate":0.079591}],"exchange":"NASDAQ","name":"Gyre Therapeutics","nameEN":"Gyre Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gyre Therapeutics(GYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Gyre Therapeutics(GYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Gyre Therapeutics,GYRE,Gyre Therapeutics股票,Gyre Therapeutics股票老虎,Gyre Therapeutics股票老虎国际,Gyre Therapeutics行情,Gyre Therapeutics股票行情,Gyre Therapeutics股价,Gyre Therapeutics股市,Gyre Therapeutics股票价格,Gyre Therapeutics股票交易,Gyre Therapeutics股票购买,Gyre Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gyre Therapeutics(GYRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Gyre Therapeutics(GYRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}